Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 60549021X | ||
| 003 | CHVBK | ||
| 005 | 20210128100503.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0674-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0674-6 | ||
| 245 | 0 | 0 | |a Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma |h [Elektronische Daten] |c [Tatsuo Masubuchi, Yuichiro Tada, Shin-ichiro Maruya, Yoshiyuki Osamura, Shin-etsu Kamata, Kouki Miura, Chihiro Fushimi, Hideaki Takahashi, Daisuke Kawakita, Seiji Kishimoto, Toshitaka Nagao] |
| 520 | 3 | |a Background: Salivary duct carcinoma (SDC) is a highly aggressive disease which often metastasizes to distant sites, and there is no established standard therapy for this systemic disease. Given that SDC is biologically similar to breast and prostate cancer, anti-androgenic receptor (AR) and anti-human epidermal growth factor receptor 2 (HER2) therapies have the potential to exert effects, not only on patients with breast and prostate cancer but also on those with SDC. Methods: The expression levels of HER2, epidermal growth factor receptor (EGFR), Ki-67, and AR were assessed in 32 patients with SDC, and their correlations with overall survival (OS) and disease-free survival (DFS) were analyzed retrospectively. SDC was classified into five subtypes using a method similar to that used for breast cancer. Results: Anti-AR, HER2, and EGFR were positive in 23 (71.9%), 14 (43.8%), and 26 (81.3%) cases, respectively. One or more of these 3 factors were positive in 30 (93.8%) cases. The Ki-67 labeling index was greater than 15% in all cases. While molecular status did not correlate with OS, EGFR and AR positivity were significantly associated with DFS in univariate analysis. Multivariate analysis revealed that EGFR was the only independent predictor of DFS. Conclusions: The statuses of some molecules are useful to predict DFS in patients with SDC. Ki-67 overexpression suggests that cytotoxic agents are effective for SDC. Since the majority of SDCs express AR, HER2, and/or EGFR, assessing and targeting these molecules are promising strategies to improve the prognosis of unresectable, metastatic or recurrent SDC, and a classification system according to the molecular expression status may be useful to select appropriate therapy. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Salivary duct carcinoma |2 nationallicence | |
| 690 | 7 | |a Androgen receptor |2 nationallicence | |
| 690 | 7 | |a HER2 |2 nationallicence | |
| 690 | 7 | |a Ki-67 |2 nationallicence | |
| 690 | 7 | |a EGFR |2 nationallicence | |
| 700 | 1 | |a Masubuchi |D Tatsuo |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Tada |D Yuichiro |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Maruya |D Shin-ichiro |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Osamura |D Yoshiyuki |u Center for Diagnostic Pathology, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kamata |D Shin-etsu |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Miura |D Kouki |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Fushimi |D Chihiro |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Takahashi |D Hideaki |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kawakita |D Daisuke |u Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan |4 aut | |
| 700 | 1 | |a Kishimoto |D Seiji |u Department of Head and Neck Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8519, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Nagao |D Toshitaka |u Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023, Tokyo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 35-44 |x 1341-9625 |q 20:1<35 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0674-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0674-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Masubuchi |D Tatsuo |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tada |D Yuichiro |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Maruya |D Shin-ichiro |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Osamura |D Yoshiyuki |u Center for Diagnostic Pathology, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kamata |D Shin-etsu |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Miura |D Kouki |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fushimi |D Chihiro |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takahashi |D Hideaki |u Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kawakita |D Daisuke |u Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kishimoto |D Seiji |u Department of Head and Neck Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8519, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nagao |D Toshitaka |u Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 35-44 |x 1341-9625 |q 20:1<35 |1 2015 |2 20 |o 10147 | ||